Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | histone arginine methyltransferase PRMT4/CARM1 | 0.0153 | 1 | 0.5 |
Onchocerca volvulus | 0.0123 | 0.6649 | 0.5 | |
Entamoeba histolytica | hypothetical protein | 0.0062 | 0 | 0.5 |
Entamoeba histolytica | arginine N-methyltransferase protein, putative | 0.0062 | 0 | 0.5 |
Echinococcus multilocularis | histone arginine methyltransferase CARMER | 0.0153 | 1 | 0.5 |
Schistosoma mansoni | protein arginine n-methyltransferase | 0.0153 | 1 | 0.5 |
Trypanosoma brucei | Protein arginine N-methyltransferase 1 catalytic subunit | 0.0062 | 0 | 0.5 |
Trypanosoma cruzi | arginine N-methyltransferase, putative | 0.0062 | 0 | 0.5 |
Echinococcus granulosus | histone arginine methyltransferase CARMER | 0.0153 | 1 | 0.5 |
Trypanosoma cruzi | arginine N-methyltransferase, putative | 0.0062 | 0 | 0.5 |
Loa Loa (eye worm) | Carm1-pending protein | 0.0153 | 1 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.